TRDA Stock Analysis: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$5.85
-0.54 (-8.39%)
▼
5d:
-16.5%
30d:
-58.22%
90d:
-46.96%
WAIT
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TRDA is down 16.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TRDA is down 16.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $5.84, which is considered oversold relative to its 30-day fair value range of $10.22 to $15.42.
Technical Outlook: Technically, TRDA is showing sideways momentum. The price is currently testing key support at $5.73. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.50 (+205.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TRDA is showing sideways momentum. The price is currently testing key support at $5.73. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.50 (+205.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.22 -
$15.42
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.4%)
- BULLISH: Trading 205.6% below Wall St target ($19.50)
- WARNING: Recommendation downgraded due to -16.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$10.22 -
$15.42
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.73
Resistance Level
$16.45
Current Trend
Sideways
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.87
Wall Street Target
$19.50
(+205.6%)
Revenue Growth (YoY)
-95.7%
Share & Embed Analysis
Last updated: May 18, 2026 3:35 PM ET
Data refreshes hourly during market hours. Next update: 4:35 PM
Data refreshes hourly during market hours. Next update: 4:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Kory James Wentworth
SELL
2500 shares
2026-04-01
Kory James Wentworth
SELL
11388 shares
2026-03-10
Nathan J Dowden
SELL
11894 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 45 HOLD |